371 related articles for article (PubMed ID: 19275964)
21. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
[TBL] [Abstract][Full Text] [Related]
22. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
24. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
25. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
Pei Z; Li X; Longenecker K; von Geldern TW; Wiedeman PE; Lubben TH; Zinker BA; Stewart K; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Long M; Wells H; Kempf-Grote AJ; Madar DJ; McDermott TS; Bhagavatula L; Fickes MG; Pireh D; Solomon LR; Lake MR; Edalji R; Fry EH; Sham HL; Trevillyan JM
J Med Chem; 2006 Jun; 49(12):3520-35. PubMed ID: 16759095
[TBL] [Abstract][Full Text] [Related]
26. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Takakura S; Mutoh S
Acta Diabetol; 2010 Mar; 47(1):43-8. PubMed ID: 19238312
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.
Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Hatayama A; Yamamoto S; Kishikawa K; Nakai H; Toda M
Bioorg Med Chem; 2008 Feb; 16(4):1613-31. PubMed ID: 18039579
[TBL] [Abstract][Full Text] [Related]
28. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; Liu S; McClure LD; McPherson RK; Olson TV; Orena SJ; Parker JC; Rocke BN; Soeller WC; Soglia CB; Treadway JL; Vanvolkenburg MA; Zhao Z; Cox ED
Bioorg Med Chem Lett; 2007 Oct; 17(20):5638-42. PubMed ID: 17822893
[TBL] [Abstract][Full Text] [Related]
29. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
[TBL] [Abstract][Full Text] [Related]
30. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.
Nordhoff S; Cerezo-Gálvez S; Deppe H; Hill O; López-Canet M; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
Bioorg Med Chem Lett; 2009 Aug; 19(15):4201-3. PubMed ID: 19515557
[TBL] [Abstract][Full Text] [Related]
31. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Eckhardt M; Langkopf E; Mark M; Tadayyon M; Thomas L; Nar H; Pfrengle W; Guth B; Lotz R; Sieger P; Fuchs H; Himmelsbach F
J Med Chem; 2007 Dec; 50(26):6450-3. PubMed ID: 18052023
[TBL] [Abstract][Full Text] [Related]
32. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.
Kato N; Oka M; Murase T; Yoshida M; Sakairi M; Yamashita S; Yasuda Y; Yoshikawa A; Hayashi Y; Makino M; Takeda M; Mirensha Y; Kakigami T
Bioorg Med Chem; 2011 Dec; 19(23):7221-7. PubMed ID: 22019046
[TBL] [Abstract][Full Text] [Related]
33. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
34. (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Nitta A; Fujii H; Sakami S; Nishimura Y; Ohyama T; Satoh M; Nakaki J; Satoh S; Inada C; Kozono H; Kumagai H; Shimamura M; Fukazawa T; Kawai H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5435-8. PubMed ID: 18819797
[TBL] [Abstract][Full Text] [Related]
35. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
[TBL] [Abstract][Full Text] [Related]
36. 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.
Nishio Y; Kimura H; Sawada N; Sugaru E; Horiguchi M; Ono M; Furuta Y; Sakai M; Masui Y; Otani M; Hashizuka T; Honda Y; Deguchi J; Nakagawa T; Nakahira H
Bioorg Med Chem; 2011 Sep; 19(18):5490-9. PubMed ID: 21865048
[TBL] [Abstract][Full Text] [Related]
37. Remediation of undesirable secondary interactions encountered in hydrophilic interaction chromatography during development of a quantitative LC-MS/MS assay for a dipeptidyl peptidase IV (DPP-IV) inhibitor in monkey serum.
Kadar EP; Wujcik CE
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(5-6):471-6. PubMed ID: 19162567
[TBL] [Abstract][Full Text] [Related]
38. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.
Benbow JW; Andrews KA; Aubrecht J; Beebe D; Boyer D; Doran S; Homiski M; Hui Y; McPherson K; Parker JC; Treadway J; Vanvolkenberg M; Zembrowski WJ
Bioorg Med Chem Lett; 2009 Apr; 19(8):2220-3. PubMed ID: 19285862
[TBL] [Abstract][Full Text] [Related]
39. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Meng W; Brigance RP; Chao HJ; Fura A; Harrity T; Marcinkeviciene J; O'Connor SP; Tamura JK; Xie D; Zhang Y; Klei HE; Kish K; Weigelt CA; Turdi H; Wang A; Zahler R; Kirby MS; Hamann LG
J Med Chem; 2010 Aug; 53(15):5620-8. PubMed ID: 20684603
[TBL] [Abstract][Full Text] [Related]
40. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
Yasuda N; Nagakura T; Inoue T; Yamazaki K; Katsutani N; Takenaka O; Clark R; Matsuura F; Emori E; Yoshikawa S; Kira K; Ikuta H; Okada T; Saeki T; Asano O; Tanaka I
Eur J Pharmacol; 2006 Oct; 548(1-3):181-7. PubMed ID: 16973152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
